Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384199598> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4384199598 abstract "Acute myeloid leukemia (AML) is a malignant neoplasm of the myeloid lineage characterized by the uncontrolled proliferation of immature myeloid blasts in the bone marrow and peripheral blood. AML is a heterogenous disease which occurs across the age spectrum, although with an increasing incidence with age. For decades, first-line, curative-intent therapy has been based on intensive therapy with anthracycline (typically daunorubicin or idarubicin) plus cytarabine (3+7), followed by additional consolidative chemotherapy and/or allogeneic stem cell transplantation. While improvements over the decades in overall survival have been observed, until recently this has been driven largely by advancements in supportive care leading to reduction in treatment-related mortality and allowing a greater proportion of patients (particularly older individuals) to safely undergo intensive therapy induction and consolidation. Despite this, five-year overall survival (OS) rates in older individuals are as low as 5% (age > 70). Although OS for patients age 15-39 is now in the range of 50%-60%, a large portion of patients still succumb to their disease. Cytogenetic and molecular profiling has led to defined risk categories, and complete risk stratification for all patients eligible for intensive therapy is crucial to aiding in the selection of optimal induction and post- remission therapy. In recent years, an improved understanding of AML biology and genetics has led to the approval of a number of novel therapies for patients deemed fit and unfit for intensive therapy, which may finally be moving the needle beyond 3+7. This article will review a current approach to AML induction patients eligible for intensive therapy, with a focus on the utilization of available novel agents." @default.
- W4384199598 created "2023-07-14" @default.
- W4384199598 creator A5002970103 @default.
- W4384199598 date "2023-06-07" @default.
- W4384199598 modified "2023-10-03" @default.
- W4384199598 title "Acute myeloid leukemia induction in the age of novel therapeutic agents" @default.
- W4384199598 cites W1968846332 @default.
- W4384199598 cites W2041027929 @default.
- W4384199598 cites W2137881702 @default.
- W4384199598 cites W2146862320 @default.
- W4384199598 cites W2715749014 @default.
- W4384199598 cites W2883399820 @default.
- W4384199598 cites W2977354624 @default.
- W4384199598 cites W2982353618 @default.
- W4384199598 cites W3013447738 @default.
- W4384199598 cites W3048827006 @default.
- W4384199598 cites W3114952208 @default.
- W4384199598 cites W3144004041 @default.
- W4384199598 cites W3168413847 @default.
- W4384199598 cites W4200195529 @default.
- W4384199598 cites W4224290890 @default.
- W4384199598 cites W4225324533 @default.
- W4384199598 cites W4281850397 @default.
- W4384199598 cites W4284884567 @default.
- W4384199598 doi "https://doi.org/10.58931/cht.2023.2234" @default.
- W4384199598 hasPublicationYear "2023" @default.
- W4384199598 type Work @default.
- W4384199598 citedByCount "0" @default.
- W4384199598 crossrefType "journal-article" @default.
- W4384199598 hasAuthorship W4384199598A5002970103 @default.
- W4384199598 hasBestOaLocation W43841995981 @default.
- W4384199598 hasConcept C121608353 @default.
- W4384199598 hasConcept C126322002 @default.
- W4384199598 hasConcept C143998085 @default.
- W4384199598 hasConcept C203014093 @default.
- W4384199598 hasConcept C2776802502 @default.
- W4384199598 hasConcept C2778041864 @default.
- W4384199598 hasConcept C2778461978 @default.
- W4384199598 hasConcept C2778729363 @default.
- W4384199598 hasConcept C2779117419 @default.
- W4384199598 hasConcept C2779134260 @default.
- W4384199598 hasConcept C2779282312 @default.
- W4384199598 hasConcept C2781021840 @default.
- W4384199598 hasConcept C2911091166 @default.
- W4384199598 hasConcept C530470458 @default.
- W4384199598 hasConcept C71924100 @default.
- W4384199598 hasConceptScore W4384199598C121608353 @default.
- W4384199598 hasConceptScore W4384199598C126322002 @default.
- W4384199598 hasConceptScore W4384199598C143998085 @default.
- W4384199598 hasConceptScore W4384199598C203014093 @default.
- W4384199598 hasConceptScore W4384199598C2776802502 @default.
- W4384199598 hasConceptScore W4384199598C2778041864 @default.
- W4384199598 hasConceptScore W4384199598C2778461978 @default.
- W4384199598 hasConceptScore W4384199598C2778729363 @default.
- W4384199598 hasConceptScore W4384199598C2779117419 @default.
- W4384199598 hasConceptScore W4384199598C2779134260 @default.
- W4384199598 hasConceptScore W4384199598C2779282312 @default.
- W4384199598 hasConceptScore W4384199598C2781021840 @default.
- W4384199598 hasConceptScore W4384199598C2911091166 @default.
- W4384199598 hasConceptScore W4384199598C530470458 @default.
- W4384199598 hasConceptScore W4384199598C71924100 @default.
- W4384199598 hasLocation W43841995981 @default.
- W4384199598 hasOpenAccess W4384199598 @default.
- W4384199598 hasPrimaryLocation W43841995981 @default.
- W4384199598 hasRelatedWork W2151584191 @default.
- W4384199598 hasRelatedWork W2282003157 @default.
- W4384199598 hasRelatedWork W2287550164 @default.
- W4384199598 hasRelatedWork W2305807114 @default.
- W4384199598 hasRelatedWork W2405192714 @default.
- W4384199598 hasRelatedWork W2416198014 @default.
- W4384199598 hasRelatedWork W2495138153 @default.
- W4384199598 hasRelatedWork W2939948854 @default.
- W4384199598 hasRelatedWork W2980222178 @default.
- W4384199598 hasRelatedWork W3096157081 @default.
- W4384199598 isParatext "false" @default.
- W4384199598 isRetracted "false" @default.
- W4384199598 workType "article" @default.